KR102506612B1 - 내피 기능장애 및 염증 질환의 치료 - Google Patents

내피 기능장애 및 염증 질환의 치료 Download PDF

Info

Publication number
KR102506612B1
KR102506612B1 KR1020227005920A KR20227005920A KR102506612B1 KR 102506612 B1 KR102506612 B1 KR 102506612B1 KR 1020227005920 A KR1020227005920 A KR 1020227005920A KR 20227005920 A KR20227005920 A KR 20227005920A KR 102506612 B1 KR102506612 B1 KR 102506612B1
Authority
KR
South Korea
Prior art keywords
cells
stro
cell
endothelial dysfunction
progeny
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227005920A
Other languages
English (en)
Korean (ko)
Other versions
KR20220029758A (ko
Inventor
웨인 그레고리 킴프톤
사이몬 리브스 베일리
실비우 이테스쿠
피터 고쉬
Original Assignee
메소블라스트, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메소블라스트, 아이엔씨. filed Critical 메소블라스트, 아이엔씨.
Publication of KR20220029758A publication Critical patent/KR20220029758A/ko
Application granted granted Critical
Publication of KR102506612B1 publication Critical patent/KR102506612B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
KR1020227005920A 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료 Active KR102506612B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
US61/736,361 2012-12-12
KR1020217004422A KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004422A Division KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Publications (2)

Publication Number Publication Date
KR20220029758A KR20220029758A (ko) 2022-03-08
KR102506612B1 true KR102506612B1 (ko) 2023-03-06

Family

ID=50933585

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227005920A Active KR102506612B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020157017531A Active KR102217962B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020217004422A Active KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157017531A Active KR102217962B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료
KR1020217004422A Active KR102367981B1 (ko) 2012-12-12 2013-12-12 내피 기능장애 및 염증 질환의 치료

Country Status (11)

Country Link
US (2) US20160175360A1 (https=)
EP (2) EP3556850A1 (https=)
JP (5) JP6572130B2 (https=)
KR (3) KR102506612B1 (https=)
CN (2) CN111840329B (https=)
AU (4) AU2013360024B2 (https=)
CA (1) CA2893942C (https=)
ES (1) ES2742035T3 (https=)
IL (1) IL239308A0 (https=)
SG (2) SG11201504340YA (https=)
WO (1) WO2014089623A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5542686B2 (ja) 2007-12-04 2014-07-09 プロテオバイオアクティブズ・ピーティーワイ・リミテッド 前駆細胞の保護およびその分化の調節
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
JPWO2022114111A1 (https=) * 2020-11-27 2022-06-02

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2866468C (en) 2004-09-24 2019-09-03 Mesoblast, Inc. Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
JP2008544957A (ja) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009073616A2 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8124071B2 (en) * 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
JP5542686B2 (ja) * 2007-12-04 2014-07-09 プロテオバイオアクティブズ・ピーティーワイ・リミテッド 前駆細胞の保護およびその分化の調節
JP2011526892A (ja) * 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
EP2350266B1 (en) * 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) * 2010-09-29 2012-04-12 Aidan Research And Consulting, Llc. Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
WO2012162754A1 (en) * 2011-06-03 2012-12-06 Mesoblast, Inc Methods of treating or preventing neurological diseases
KR101786862B1 (ko) * 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
CA2880808C (en) * 2012-08-01 2023-01-24 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
JP6431850B2 (ja) * 2013-01-09 2018-11-28 ユナイテッド セラピューティクス コーポレイション プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置

Also Published As

Publication number Publication date
CN105358163B (zh) 2020-09-11
JP2023030116A (ja) 2023-03-07
AU2013360024A1 (en) 2015-07-02
AU2013360024B2 (en) 2019-02-28
AU2019202960A1 (en) 2019-05-16
KR20220029758A (ko) 2022-03-08
AU2021250848A1 (en) 2021-11-04
JP2019214571A (ja) 2019-12-19
CN111840329A (zh) 2020-10-30
CN105358163A (zh) 2016-02-24
SG11201504340YA (en) 2015-07-30
SG10201705061RA (en) 2017-07-28
HK1210209A1 (en) 2016-04-15
JP2024147655A (ja) 2024-10-16
AU2019202960B2 (en) 2021-07-29
JP7201715B2 (ja) 2023-01-10
ES2742035T3 (es) 2020-02-12
AU2024227208A1 (en) 2024-10-31
KR102217962B1 (ko) 2021-02-22
KR102367981B1 (ko) 2022-02-25
US20160175360A1 (en) 2016-06-23
WO2014089623A1 (en) 2014-06-19
US20240115618A1 (en) 2024-04-11
JP2016504311A (ja) 2016-02-12
EP2931876B1 (en) 2019-05-29
JP2021073240A (ja) 2021-05-13
JP6572130B2 (ja) 2019-09-04
KR20210021104A (ko) 2021-02-24
KR20150093732A (ko) 2015-08-18
CA2893942C (en) 2023-03-28
CA2893942A1 (en) 2014-06-19
EP3556850A1 (en) 2019-10-23
EP2931876A1 (en) 2015-10-21
JP6829288B2 (ja) 2021-02-10
IL239308A0 (en) 2015-07-30
EP2931876A4 (en) 2016-05-25
CN111840329B (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
JP6505148B2 (ja) 移植片対宿主病の治療法
US20240115618A1 (en) Treatment of diseases of endothelial dysfunction and inflammation
US10159696B2 (en) Methods for treating obesity and/or metabolic syndrome
HK40014520A (en) Treatment of diseases of endothelial dysfunction and inflammation
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4